These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12431041)

  • 1. Ocular tolerability and safety of ketotifen fumarate ophthalmic solution.
    Abelson MB; Chapin MJ; Kapik BM; Shams NB
    Adv Ther; 2002; 19(4):161-9. PubMed ID: 12431041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ
    Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.
    Abelson MB; Ferzola NJ; McWhirter CL; Crampton HJ
    Pediatr Allergy Immunol; 2004 Dec; 15(6):551-7. PubMed ID: 15610370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis.
    Torkildsen GL; Abelson MB; Gomes PJ
    Clin Ther; 2008 Jul; 30(7):1272-82. PubMed ID: 18691986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis.
    Kidd M; McKenzie SH; Steven I; Cooper C; Lanz R;
    Br J Ophthalmol; 2003 Oct; 87(10):1206-11. PubMed ID: 14507747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model.
    Abelson MB; Chapin MJ; Kapik BM; Shams NB
    Arch Ophthalmol; 2003 May; 121(5):626-30. PubMed ID: 12742839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single dose of ketotifen fumarate .025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitis.
    Greiner JV; Michaelson C; McWhirter CL; Shams NB
    Adv Ther; 2002; 19(4):185-93. PubMed ID: 12431044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis.
    Greiner JV; Mundorf T; Dubiner H; Lonsdale J; Casey R; Parver L; Kapik BM; Shams NB; Abelson MB
    Am J Ophthalmol; 2003 Dec; 136(6):1097-105. PubMed ID: 14644221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real-world comparison of efficacy and ocular comfort.
    Ganz M; Koll E; Gausche J; Detjen P; Orfan N
    Adv Ther; 2003; 20(2):79-91. PubMed ID: 12836808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model.
    D'Arienzo PA; Leonardi A; Bensch G
    Clin Ther; 2002 Mar; 24(3):409-16. PubMed ID: 11952024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model.
    Greiner JV; Minno G
    Clin Ther; 2003 Jul; 25(7):1988-2005. PubMed ID: 12946546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model.
    Crampton HJ
    Clin Ther; 2002 Nov; 24(11):1800-8. PubMed ID: 12501875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allergic contact dermatitis in response to ketotifen fumarate contained in eye drops.
    Romita P; Stingeni L; Barlusconi C; Hansel K; Foti C
    Contact Dermatitis; 2020 Jul; 83(1):35-37. PubMed ID: 32064627
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis.
    Mortemousque B; Bourcier T; Khairallah M; Messaoud R; Brignole-Baudouin F; Renault D; Rebika H; Brémond-Gignac D;
    J Fr Ophtalmol; 2014 Jan; 37(1):1-8. PubMed ID: 24388379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Tolerability of Ketotifen in the Treatment Of Seasonal Allergic Conjunctivitis: Comparison between Ketotifen 0.025% and 0.05% Eye Drops.
    Leonardi A; Capobianco D; Benedetti N; Capobianco A; Cavarzeran F; Scalora T; Modugno R; Feuerman OM
    Ocul Immunol Inflamm; 2019; 27(8):1352-1356. PubMed ID: 30303746
    [No Abstract]   [Full Text] [Related]  

  • 18. [Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis].
    Hida WT; Nogueira DC; Schaefer A; Dantas PE; Dantas MC
    Arq Bras Oftalmol; 2006; 69(6):851-6. PubMed ID: 17273679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM; Tekelioglu Y; Turk A; Akyol N
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic Conjunctivitis.
    Gomes PJ; Ciolino JB; Arranz P; Hernández G; Fernández N
    J Investig Allergol Clin Immunol; 2024 Jun; 34(3):167-176. PubMed ID: 36811846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.